Abstract
PURPOSE: The aim of this study was to evaluate the role of 18F-FDG PET/CT performed after surgery but before radioiodine therapy in patients with differentiated thyroid cancer. PROCEDURES: FDG PET/CT was performed off l-thyroxine in 60 newly diagnosed differentiated thyroid cancer patients. Clinical and hematological evaluation as well as high-resolution neck ultrasound were performed. All patients underwent a complete follow-up (range, 6-67 months; mean [SD], 31.7 [20.6] months). The date of recurrence or the most recent office visit was recorded. Progression-free survival (PFS) is the primary end point of this study. Analysis was performed by Cox proportional hazards model. Survival curves were generated using Kaplan-Meier estimates, and the log-rank test was used to assess significance. RESULTS: FDG PET/CT was negative in 63% of patients, 20% had FDG thyroid bed uptake, 5% distant metastases, and 12% lymph node FDG uptake. In patients with positive FDG PET/CT scan (ie, those with distant metastases or lymph node uptake), a higher rate of recurrence was observed (50% vs 6%, P <0.05). Thyroglobulin, neck ultrasound, stage, and FDG PET/CT correlated with PFS at univariate analysis. At multivariate analysis, only thyroglobulin and FDG PET/CT continued to be predictors of PFS. Patients with a negative FDG PET/CT scan have a better PFS either in the whole group or in those with elevated thyroglobulin level (both >2 ng/mL and >10 ng/mL). CONCLUSIONS: FDG PET/CT was abnormal in 17% of patients. Moreover, FDG PET/CT has an independent prognostic role, with a better PFS in patients with a negative scan.
| Original language | English |
|---|---|
| Pages (from-to) | 111-115 |
| Number of pages | 5 |
| Journal | Clinical Nuclear Medicine |
| Volume | 40 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 21 2015 |
Fingerprint
Keywords
- differentiated thyroid cancer
- FDG PET/CT
- progression-free survival
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Medicine(all)
Cite this
Prognostic role of 18F-FDG PET/CT in the postoperative evaluation of differentiated thyroid cancer patients. / Pace, Leonardo; Klain, Michele; Salvatore, Barbara; Nicolai, Emanuele; Zampella, Emilia; Assante, Roberta; Pellegrino, Teresa; Storto, Giovanni; Fonti, Rosa; Salvatore, Marco.
In: Clinical Nuclear Medicine, Vol. 40, No. 2, 21.02.2015, p. 111-115.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prognostic role of 18F-FDG PET/CT in the postoperative evaluation of differentiated thyroid cancer patients
AU - Pace, Leonardo
AU - Klain, Michele
AU - Salvatore, Barbara
AU - Nicolai, Emanuele
AU - Zampella, Emilia
AU - Assante, Roberta
AU - Pellegrino, Teresa
AU - Storto, Giovanni
AU - Fonti, Rosa
AU - Salvatore, Marco
PY - 2015/2/21
Y1 - 2015/2/21
N2 - PURPOSE: The aim of this study was to evaluate the role of 18F-FDG PET/CT performed after surgery but before radioiodine therapy in patients with differentiated thyroid cancer. PROCEDURES: FDG PET/CT was performed off l-thyroxine in 60 newly diagnosed differentiated thyroid cancer patients. Clinical and hematological evaluation as well as high-resolution neck ultrasound were performed. All patients underwent a complete follow-up (range, 6-67 months; mean [SD], 31.7 [20.6] months). The date of recurrence or the most recent office visit was recorded. Progression-free survival (PFS) is the primary end point of this study. Analysis was performed by Cox proportional hazards model. Survival curves were generated using Kaplan-Meier estimates, and the log-rank test was used to assess significance. RESULTS: FDG PET/CT was negative in 63% of patients, 20% had FDG thyroid bed uptake, 5% distant metastases, and 12% lymph node FDG uptake. In patients with positive FDG PET/CT scan (ie, those with distant metastases or lymph node uptake), a higher rate of recurrence was observed (50% vs 6%, P <0.05). Thyroglobulin, neck ultrasound, stage, and FDG PET/CT correlated with PFS at univariate analysis. At multivariate analysis, only thyroglobulin and FDG PET/CT continued to be predictors of PFS. Patients with a negative FDG PET/CT scan have a better PFS either in the whole group or in those with elevated thyroglobulin level (both >2 ng/mL and >10 ng/mL). CONCLUSIONS: FDG PET/CT was abnormal in 17% of patients. Moreover, FDG PET/CT has an independent prognostic role, with a better PFS in patients with a negative scan.
AB - PURPOSE: The aim of this study was to evaluate the role of 18F-FDG PET/CT performed after surgery but before radioiodine therapy in patients with differentiated thyroid cancer. PROCEDURES: FDG PET/CT was performed off l-thyroxine in 60 newly diagnosed differentiated thyroid cancer patients. Clinical and hematological evaluation as well as high-resolution neck ultrasound were performed. All patients underwent a complete follow-up (range, 6-67 months; mean [SD], 31.7 [20.6] months). The date of recurrence or the most recent office visit was recorded. Progression-free survival (PFS) is the primary end point of this study. Analysis was performed by Cox proportional hazards model. Survival curves were generated using Kaplan-Meier estimates, and the log-rank test was used to assess significance. RESULTS: FDG PET/CT was negative in 63% of patients, 20% had FDG thyroid bed uptake, 5% distant metastases, and 12% lymph node FDG uptake. In patients with positive FDG PET/CT scan (ie, those with distant metastases or lymph node uptake), a higher rate of recurrence was observed (50% vs 6%, P <0.05). Thyroglobulin, neck ultrasound, stage, and FDG PET/CT correlated with PFS at univariate analysis. At multivariate analysis, only thyroglobulin and FDG PET/CT continued to be predictors of PFS. Patients with a negative FDG PET/CT scan have a better PFS either in the whole group or in those with elevated thyroglobulin level (both >2 ng/mL and >10 ng/mL). CONCLUSIONS: FDG PET/CT was abnormal in 17% of patients. Moreover, FDG PET/CT has an independent prognostic role, with a better PFS in patients with a negative scan.
KW - differentiated thyroid cancer
KW - FDG PET/CT
KW - progression-free survival
UR - http://www.scopus.com/inward/record.url?scp=84921468312&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84921468312&partnerID=8YFLogxK
U2 - 10.1097/RLU.0000000000000621
DO - 10.1097/RLU.0000000000000621
M3 - Article
VL - 40
SP - 111
EP - 115
JO - Clinical Nuclear Medicine
JF - Clinical Nuclear Medicine
SN - 0363-9762
IS - 2
ER -